CelLBxHealth (AIM:CLBX) shares rocketed, rising 35.1% to 2.35p, after signing a Master Services Agreement with AstraZeneca.
"We are delighted to enter into this Master Services Agreement which enables AstraZeneca to access our capabilities across their development pipeline," said Peter Collins, Chief Executive Officer.
The company's patent-protected Parsortix platform harvests CTCs from blood and can be integrated with existing laboratory instruments for downstream whole-cell imaging, proteomic profiling and full genomic workflows.
CelLBxHealth's commercial model spans product sales of the Parsortix platform and consumables via CRO and clinical lab partnerships, laboratory services including clinical trial support and assay development from a GCLP-compliant UK facility, and lab-developed tests pursued through strategic partnerships and in-house development.
